AR059120A2 - Sal de dicarboxilato del (1s,4r) -4- (2-amino-6- (ciclopropilamino ) -9h- purin-9-il)-2- ciclopenten -1- metanol y procedimiento para su preparacion - Google Patents

Sal de dicarboxilato del (1s,4r) -4- (2-amino-6- (ciclopropilamino ) -9h- purin-9-il)-2- ciclopenten -1- metanol y procedimiento para su preparacion

Info

Publication number
AR059120A2
AR059120A2 ARP070100006A ARP070100006A AR059120A2 AR 059120 A2 AR059120 A2 AR 059120A2 AR P070100006 A ARP070100006 A AR P070100006A AR P070100006 A ARP070100006 A AR P070100006A AR 059120 A2 AR059120 A2 AR 059120A2
Authority
AR
Argentina
Prior art keywords
preparation
purin
methanol
amino
procedure
Prior art date
Application number
ARP070100006A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10812407&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059120(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR059120A2 publication Critical patent/AR059120A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)

Abstract

Un sal que es dicarboxilato del (1S,4R)-4-[2-amino-6-(ciclopropilamino)-9H-purin-9-il]-2-ciclopenten-1-metanol, donde el dicarboxilato se selecciona del grupo que consiste de glutarato, hemisuberato, adipato, fumarato, hemisebacato y pimetato y proceso para su preparacion y procedimiento para su preparacion. Reivindicacion 3: Un proceso para la preparacion del compuesto segun la reivindicacion 1, caracterizado porque comprende: agregar ácido sulfurico a (1S,4R)-4-[2-amino-6- (ciclopropilamino)-8H-purin-9-il]-2-ciclopenten-1-metanol en una proporcion estequeométrica de 1:2
ARP070100006A 1997-05-17 2007-01-02 Sal de dicarboxilato del (1s,4r) -4- (2-amino-6- (ciclopropilamino ) -9h- purin-9-il)-2- ciclopenten -1- metanol y procedimiento para su preparacion AR059120A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt

Publications (1)

Publication Number Publication Date
AR059120A2 true AR059120A2 (es) 2008-03-12

Family

ID=10812407

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102251A AR015668A1 (es) 1997-05-17 1998-05-14 Sal de hemisulfato de (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol y formulacion farmaceutica que la contiene
ARP070100006A AR059120A2 (es) 1997-05-17 2007-01-02 Sal de dicarboxilato del (1s,4r) -4- (2-amino-6- (ciclopropilamino ) -9h- purin-9-il)-2- ciclopenten -1- metanol y procedimiento para su preparacion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102251A AR015668A1 (es) 1997-05-17 1998-05-14 Sal de hemisulfato de (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol y formulacion farmaceutica que la contiene

Country Status (51)

Country Link
US (1) US6294540B1 (es)
EP (1) EP0983271B1 (es)
JP (2) JP3150711B2 (es)
KR (1) KR100521292B1 (es)
CN (2) CN100408580C (es)
AP (1) AP2009A (es)
AR (2) AR015668A1 (es)
AT (1) ATE259811T1 (es)
AU (1) AU739953B2 (es)
BG (1) BG64390B1 (es)
BR (1) BRPI9809126B8 (es)
CA (1) CA2289753C (es)
CO (1) CO4940435A1 (es)
DE (1) DE69821758T2 (es)
DK (1) DK0983271T3 (es)
DZ (1) DZ2493A1 (es)
EA (1) EA001809B1 (es)
EE (1) EE03924B1 (es)
EG (1) EG23836A (es)
ES (1) ES2214712T3 (es)
GB (3) GB9709945D0 (es)
GE (1) GEP20022680B (es)
HK (1) HK1024236A1 (es)
HN (1) HN1998000071A (es)
HR (1) HRP980265B1 (es)
HU (1) HU226563B1 (es)
ID (1) ID24910A (es)
IL (2) IL132793A0 (es)
IS (1) IS2207B (es)
JO (1) JO2032B1 (es)
MA (1) MA26498A1 (es)
MY (1) MY120151A (es)
NO (1) NO324731B1 (es)
NZ (2) NZ510622A (es)
OA (1) OA11304A (es)
PA (1) PA8451301A1 (es)
PE (1) PE78799A1 (es)
PL (1) PL189527B1 (es)
PT (1) PT983271E (es)
RS (1) RS49655B (es)
SA (1) SA98190179B1 (es)
SI (1) SI0983271T1 (es)
SK (1) SK285159B6 (es)
SV (1) SV1998000057A (es)
TN (1) TNSN98065A1 (es)
TR (1) TR199902810T2 (es)
TW (1) TW480259B (es)
UA (1) UA56231C2 (es)
UY (1) UY25004A1 (es)
WO (1) WO1998052949A1 (es)
ZA (2) ZA984083B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
KR101396686B1 (ko) * 2006-09-28 2014-05-16 에스티브 퀴미카 에스.에이. 아바카비어 조제 방법
EP1905772A1 (en) * 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
EP2305680A3 (en) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
NZ627826A (en) 2010-01-27 2016-01-29 Viiv Healthcare Co Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
CN103282369A (zh) 2011-04-08 2013-09-04 劳乐斯实验室私营有限公司 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物
JP6391561B2 (ja) 2013-02-27 2018-09-19 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN105315280A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种阿巴卡韦结晶体及其制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
HUP9903098A3 (en) * 1996-06-25 2000-01-28 Glaxo Group Ltd Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them

Also Published As

Publication number Publication date
PL189527B1 (pl) 2005-08-31
GB9709945D0 (en) 1997-07-09
GB2340491A (en) 2000-02-23
AR015668A1 (es) 2001-05-16
US6294540B1 (en) 2001-09-25
YU59599A (es) 2002-08-12
EA001809B1 (ru) 2001-08-27
WO1998052949A1 (en) 1998-11-26
ZA984085B (en) 2000-01-26
JO2032B1 (en) 1999-05-15
CN1515572A (zh) 2004-07-28
SA98190179B1 (ar) 2006-08-15
JP2000327679A (ja) 2000-11-28
NO995622L (no) 2000-01-14
AU7765598A (en) 1998-12-11
EE03924B1 (et) 2002-12-16
GB2340491B (en) 2000-10-18
BG64390B1 (bg) 2004-12-30
KR20010012623A (ko) 2001-02-26
HUP0002754A3 (en) 2003-01-28
OA11304A (en) 2003-10-22
DZ2493A1 (fr) 2004-06-20
EG23836A (en) 2007-10-02
HRP980265A2 (en) 1999-02-28
GEP20022680B (en) 2002-04-25
MY120151A (en) 2005-09-30
MA26498A1 (fr) 2004-12-20
ES2214712T3 (es) 2004-09-16
UA56231C2 (uk) 2003-05-15
CO4940435A1 (es) 2000-07-24
ZA984083B (en) 1999-11-15
HUP0002754A2 (hu) 2001-06-28
DE69821758D1 (de) 2004-03-25
EA199900944A1 (ru) 2000-06-26
HU226563B1 (en) 2009-04-28
JP3150711B2 (ja) 2001-03-26
JP2000514096A (ja) 2000-10-24
DE69821758T2 (de) 2005-01-13
SK285159B6 (sk) 2006-07-07
GB9926839D0 (en) 2000-01-12
AU739953B2 (en) 2001-10-25
PL336888A1 (en) 2000-07-17
EP0983271A1 (en) 2000-03-08
EP0983271B1 (en) 2004-02-18
CN1150194C (zh) 2004-05-19
AP2009A (en) 2009-06-26
UY25004A1 (es) 2000-10-31
PA8451301A1 (es) 2000-05-24
GB2348202A (en) 2000-09-27
NO324731B1 (no) 2007-12-03
IS2207B (is) 2007-02-15
BRPI9809126B8 (pt) 2021-07-06
SI0983271T1 (en) 2004-06-30
GB2348202B (en) 2001-08-08
HRP980265B1 (en) 2004-10-31
PT983271E (pt) 2004-07-30
BR9809126A (pt) 2000-08-01
BG103959A (en) 2000-12-29
DK0983271T3 (da) 2004-05-10
ATE259811T1 (de) 2004-03-15
RS49655B (sr) 2007-09-21
CA2289753C (en) 2007-01-23
HN1998000071A (es) 1999-03-19
TNSN98065A1 (fr) 2005-03-15
IL132793A (en) 2006-10-31
KR100521292B1 (ko) 2005-10-17
AP9901688A0 (en) 1999-12-31
IS5246A (is) 1999-11-11
NZ510622A (en) 2002-04-26
GB0010222D0 (en) 2000-06-14
PE78799A1 (es) 1999-08-31
IL132793A0 (en) 2001-03-19
SK156199A3 (en) 2000-07-11
ID24910A (id) 2000-08-31
HK1024236A1 (en) 2000-10-05
CA2289753A1 (en) 1998-11-26
TR199902810T2 (xx) 2000-02-21
SV1998000057A (es) 1999-03-02
BRPI9809126B1 (pt) 2018-02-06
CN100408580C (zh) 2008-08-06
NO995622D0 (no) 1999-11-16
CN1263529A (zh) 2000-08-16
EE9900537A (et) 2000-06-15
NZ500865A (en) 2001-04-27
TW480259B (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AR059120A2 (es) Sal de dicarboxilato del (1s,4r) -4- (2-amino-6- (ciclopropilamino ) -9h- purin-9-il)-2- ciclopenten -1- metanol y procedimiento para su preparacion
BRPI9917718B8 (pt) bactéria pertencente ao gênero escherichia e tendo uma capacidade para produzir um l-aminoácido selecionado do grupo que consiste de ácido l-glutâmico, l-histidina, l-prolina e l-treonina, e, processo para produzir um l-aminoácido selecionado do grupo que consiste de ácido l-glutâmico, l-histidina, l-prolina e l-treonina.
ATE72229T1 (de) Verfahren zur herstellung von serin-n,ndiessigs|ure und derivaten.
ES2132676T3 (es) Composiciones de peroxigeno.
ATE172963T1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
BR0100765A (pt) Processo para o processamento de composições de borracha contendo ácidos graxos de soja, ácidos graxos de girassol e suas misturas
ES2159919T3 (es) Procedimiento para la preparacion de compuestos de tipo ceramidas.
EP0418797A3 (en) Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds
ATE282317T1 (de) Antimikrobielle zusammensetzung zur behandlung von rindermastitis
RU93033091A (ru) Композиция и способы идентификации раствора
BR0000997A (pt) Processo para preparação de ácido (met) acrìlico
ES2145417T3 (es) Procedimiento para la preparacion de soluciones de sales de aluminio.
ES2013287B3 (es) Procedimiento para separar metales de aguas que los contienen.
DE59309891D1 (de) Verfahren zur herstellung von tensidgranulaten
DE69518901D1 (de) Verfahren zur Herstellung von Xylitol
FI883310A0 (fi) Rengoeringsmedelkomposition och dess anvaendning.
BR9812324A (pt) Métodos e dispositivos para remover ácido acético de ciclo-hexano na produção de ácido adìpico
ATE217902T1 (de) Monophasige konzentriente wässerige lösungen von tetrahydroiso-alpha-säuren und verfahren zu deren herstellung
BR9908965A (pt) Processos aperfeiçoados para sìntese e purificação de gorduras não-digerìveis
ATE397088T1 (de) Verfahren zur herstellung von (s)- oder (r)-3,3,3-trifluor-2-hydroxy-2-methylpropionsaü e
ATE69795T1 (de) Verfahren zur herstellung von ethylenischen carbonylverbindungen.
DE50004903D1 (de) Verfahren zur Herstellung von Isobornylmethacrylat
PL310655A1 (en) Derivatives of hydroxymethylfurasane carboxylic acid and their application in treating cardiovascular diseases
ES2183860T3 (es) Procedimiento para producir n-terc butil-2-pirazincarboxamida y n-ter-butil-2-piperazincarboxamida.
ES8503942A1 (es) Procedimiento de coloracion de faneros con colorantes naturales

Legal Events

Date Code Title Description
FG Grant, registration